Loading…
Unexo Lifesciences, a drug manufacturer in New Delhi, India, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered its finished pharmaceutical products adulterated. The company's quality control and assurance units failed to exercise adequate oversight of drug product compliance, data reliability, and employee adherence to data integrity principles, with specific deficiencies including incomplete batch production and control records, some of which were found torn and stored improperly on the facility's rooftop. The FDA conducted an inspection from May 1-14, 2024, and issued this warning letter on November 6, 2024, following the company's June response to initial inspection findings.